**Reviewer Comments and Suggestions**

**Title: WHO Approach towards the development of a global regulatory framework for cell and gene therapy products**

**(document WHO/BS/2022.2424)**

|  |  |
| --- | --- |
| Written comments proposing modifications to this Guideline MUST be received by **9 September 2022.**  Comments should be submitted electronically to the Responsible Officer: Dr. Richard Isbrucker at: [isbruckerr@who.int](mailto:isbruckerr@who.int) | |
| Reviewer(s)  (Name, Organization, and contact details): |  |

| *(please insert additional rows as necessary)* | | | | |
| --- | --- | --- | --- | --- |
| Line No. | Original Text | Comment | Suggested Amendment | Internal Use Only |
| **General / Overall comments on the document:** | | | | |
|  | | | |  |
|  | | | |  |
|  | | | |  |
|  | | | |  |
|  | | | |  |
| **1. Introduction** | | | | |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| **2. Purpose** | | | | |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| **3. Terminology** | | | | |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| **4. Classification of HCTs and ATMPs** | | | | |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| **5. Regulatory expectations for HCTs and ATMPs** | | | | |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| **6. A risk-based approach for the regulatory oversight of HCTs and ATMPs** | | | | |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| **7. Considerations in th edevelopment of a regulatory framework** | | | | |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| **8. Collaboration and strengthening regulatory capacities for the oversight of HCTs and ATMPs** | | | | |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| **9. Conclusion and next steps** | | | | |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| **Acknowledgements, References, Appendix 1** | | | | |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| **Table 1** | | | | |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| **Figure 1** | | | | |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |